Article

Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events

2024-06-11

Abstract excerpt

<h4>Introduction</h4> Immune checkpoint inhibitors (ICIs) can yield remarkable clinical responses in subsets of patients with solid tumors but can also often lead to immune-related adverse events (irAEs). Predictive features of clinically severe irAEs leading to cessation of ICIs have yet to be established. Using data from 1,327 patients with lung cancer treated with ICIs between 2009 and 2022 at four academic med...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 62197470-ad84-5022-a7cb-bf1dc1685e7b
DOI: 10.1101/2024.06.10.24308518

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse eventsDOI 10.1101/2024.06.10.24308518Read

Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation.Semantic proximity Read

Germline genetic variation and predicting immune checkpoint inhibitor induced toxicitySemantic proximity Read

Germline variants associated with immunotherapy-related adverse eventsSemantic proximity Read

Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint BlockadeSemantic proximity Read

Discontinuation Risk from Adverse Events: Immunotherapy Alone vs. Combined with Chemotherapy: A Systematic Review and Network Meta-analysisSemantic proximity Read

Germline mechanisms of immunotherapy toxicities in the era of genome‐wide association studiesSemantic proximity Read

Construction and evaluation of clinical prediction model for immunotherapy-related adverse events and clinical benefit in cancer patients receiving immune checkpoint inhibitors based on serum cytokine levelsSemantic proximity Read

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse eventsSemantic proximity Read

The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patientsSemantic proximity Read

Thyroid-related Adverse Events Caused by Immune Checkpoint Inhibitors Associated with Therapeutic Outcomes in Cancer Patients: a systematic review and meta-analysisSemantic proximity Read

Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies.Semantic proximity Read

A real-world data analysis of the impact of clonal hematopoiesis of indeterminate potential on therapeutic efficacy and adverse events of immune checkpoint inhibitors.Semantic proximity Read